Research site

Cullman, Alabama 35058

2 studies enrolling now · 14 studies all time

What they study most

COPD (Chronic Obstructive Pulmonary Disease), COVID-19, Chronic Obstructive Pulmonary Disease (COPD), Corona Virus Disease, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Relapsing Forms of Multiple Sclerosis, Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis

Studies at this site

• A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) — Recruiting now
• A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Recruiting now
• Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study — Completed
• Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD) — Completed
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis — Completed
• Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States — Completed
• Rebif® Rebidose® Versus Rebiject II® Ease-of-Use — Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab — Completed
• Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) — Completed
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis — Completed
• Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis — Stopped early
• Treatment Interruption of Natalizumab — Completed